Understanding Medical Cannabis Use in Older Adults:
Key Insights from Recent Research
Older adults represent one of the fastest-growing demographic groups in Canada using cannabis. According to Statistics Canada, approximately 40,000 seniors (aged 65 years and older) reported cannabis use in 2012. By 2019, this number had increased more than tenfold to over 400,000 seniors reporting cannabis use in the past three months – a trend that continues to rise (Statistics Canada, 2019). Given the rapid rise in cannabis use among older adults, many of whom live with multiple comorbidities and complex medication regimens, there is a growing need for real-world evidence to guide safe clinical use. Dr. Pearson and colleagues set out to examine the real-world effects of medical cannabis, focusing on the health and well-being of patients aged 50 years and older with pain and sleep concerns. In this article, we explore some of the key findings from their research.
DID YOU KNOW? Research examining cannabis use among older adults consistently identifies pain, sleep, and anxiety as the most common reasons for use. A recent publication by the Public Health Agency of Canada found that older adults frequently cite arthritis, chronic pain, insomnia, stress, and anxiety as key motivations for cannabis use (Public Health Agency of Canada, 2025).
_________________________________________________________________________________
“This study adds important real-world data to our understanding of how medical cannabis can support older adults dealing with pain, sleep disturbances, and reduced quality of life. With clinical supervision and an individualized approach, cannabis offers a safe and effective option — not only for improving multiple symptoms simultaneously, but also for reducing the number of medications required. That’s especially important in older adults, where polypharmacy increases the risk of adverse drug events.”
— Dr. Blake Pearson, MD
OVERVIEW OF THE STUDY
The Medical Cannabis in Older Patients Study (MCOPS) was a multi-site, prospective observational study examining the real-world impact of medical cannabis use in patients aged 50 years and older under healthcare professional supervision.
Over a six-month period, 299 participants were monitored for changes in pain, sleep, and overall quality of life. Data was collected using seven patient- and physician-administered surveys and questionnaires to capture both subjective and objective outcomes respectively at baseline, 3-and 6-month timepoints.
WHY THIS MATTERS:
Understanding patterns of use in older adults, along with evidence on therapeutic benefits and safety profiles from this study, helps healthcare providers make more informed, patient-centered decisions that balance efficacy and safety.
PATTERNS OF USE:
- The majority of participants (95.9%) reported using orally administered products as their primary method of consumption.
- Among these, CBD-dominant formulations were most preferred, followed by balanced THC/CBD and THC dominant products.
- Patients used cannabis on average twice daily.
KEY FINDINGS:
Improved Pain:
- Brief Pain Inventory (BPI) scores for both pain severity and pain interference (the extent to which pain affects daily activities) decreased significantly at 3 and 6 months in comparison to baseline. Clinically meaningful improvements were observed in 31% of patients for pain severity and in 45% for pain interference.
Table 1. Changes in BPI Scores from Baseline to M3 and M6.
Note. Reproduced from “Medical Cannabis for Patients Over Age 50: A Multi-site, Prospective Study of Patterns of Use and Health Outcomes,” by B. Pearson, M. Walker, J. Tempero, K. Ong, P. Lucas, and Social Dimensions of Health, University of Victoria, Cannabis, 8(1), 81–94 (2025), https://doi.org/10.26828/cannabis/2024/000239. Licensed under CC BY 4.0.
Improved Sleep:
- Statistically significant improvements in sleep quality were observed at both M3 and M6. Nearly 45% of participants experienced a clinically meaningful improvement in sleep quality.
Enhanced Quality of Life:
- Patients reported statistically significant improvements in overall quality of life from baseline to M3 and M6, with the greatest improvements observed in ability to perform usual activities, pain/discomfort, and anxiety/depression, as measured by the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire.
Reduced Use of Other Medications:
- A decrease was observed in the percentage of patients using several classes of medications from baseline to M3 and M6 (with the exception of benzodiazepines and antiseizure medications). A statistically significant reduction in pain medications (e.g., opioids, non-opioids and others) was noted over time.
Figure 1. Decline in Use of Pain Medications Among Patients Using Those Medications at Baseline.
Note. Reproduced from “Medical Cannabis for Patients Over Age 50: A Multi-site, Prospective Study of Patterns of Use and Health Outcomes,” by B. Pearson, M. Walker, J. Tempero, K. Ong, P. Lucas, and Social Dimensions of Health, University of Victoria, Cannabis, 8(1), 81–94 (2025), https://doi.org/10.26828/cannabis/2024/000239. Licensed under CC BY 4.0.
Minimal Side Effects:
- Fewer than 5% of participants reported adverse events, with no serious adverse events observed. The most commonly reported side effects were dizziness, drowsiness, nausea/vomiting and feeling “too high”.
_____________________________________________________________________________________________
KEY RECOMMENDATIONS FOR CLINICAL PRACTICE:
Based on these findings, healthcare providers are encouraged to consider the following practical points:
- Be aware and ask about cannabis use in older patients: Cannabis use is increasingly common among older adults. Ask about cannabis use during assessments to identify potential drug interactions or adverse effects.
- Use an individualized, clinically supervised approach: Given that older adults often have multiple co-morbidities and are taking several medications (i.e., poly-pharmacy), medical cannabis should be initiated under healthcare professional supervision, with a start low, go slow approach to assess response and tolerance. Oral formulations are preferred, as they allow for more precise dosing and avoid the risks associated with smoked products.
- Monitor co-medications and adjust gradually: As observed in this study, patients may reduce their use of pain and other medications over time. Reassess medication needs regularly through ongoing clinical monitoring, and counsel patients on the importance of not abruptly discontinuing medications without a supervised tapering plan.
- Educate and support safe use: Provide guidance on potential side effects, interactions, and safe storage or administration practices.
DID YOU KNOW? MyMedi.ca offers free pharmacist consultations. Our team of cannabis-trained pharmacists can help answer questions about medical cannabis, including dose titration, side effects, drug interactions, and more.
HAVE ANY QUESTIONS?
Contact Us
For additional information about courses, please contact us.
